Ownership and insider activity for Oruka Therapeutics, Inc. (ORKA): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Price
| Price | $99.55 (closing price, November 3, 2026) |
| Market Cap | $6.6B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-20 | Quinlan Paul T | M-Exempt | 9,000 | $70K |
| 2026-10-20 | Quinlan Paul T | M-Exempt | 9,000 | $70K |
| 2026-10-20 | Quinlan Paul T | S-Sale | 400 | $30K |
| 2026-10-20 | Quinlan Paul T | S-Sale | 500 | $38K |
| 2026-10-20 | Quinlan Paul T | S-Sale | 1,000 | $77K |
| 2026-10-20 | Quinlan Paul T | S-Sale | 4,100 | $323K |
| 2026-10-20 | Quinlan Paul T | S-Sale | 3,000 | $238K |
| 2026-10-15 | Goncalves Joana | M-Exempt | 3,500 | $24K |
| 2026-10-15 | Goncalves Joana | M-Exempt | 3,500 | $27K |
| 2026-10-15 | Goncalves Joana | M-Exempt | 3,500 | $27K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.4M | $8.7M | $6.6M | $8.4M | $49.1M | $53.4M | $42.4M | $37.4M | $61.6M | $46.9M |
| Short-term Investments | $13.8M | $3.0M | 0 | 0 | 0 | 0 | 0 | 0 | $314.1M | $290.1M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $21.4M | $12.3M | $6.8M | $8.5M | $50.0M | $54.4M | $42.7M | $37.6M | $376.9M | $343.9M |
| Property, Plant & Equipment | $66,000 | $42,000 | $24,000 | $32,000 | $449,000 | $485,000 | $368,000 | $257,000 | $1.0M | $2.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $24.6M | $12.4M | $6.8M | $8.5M | $50.4M | $54.9M | $43.1M | $37.9M | $396.0M | $488.6M |
| Accounts Payable | 0 | $622,000 | $230,000 | $418,000 | $1.8M | $1.1M | $334,000 | 0 | $3.5M | $4.2M |
| Short-term Debt | 0 | 0 | 0 | $25,000 | $41,000 | $100,000 | $103,000 | $76,000 | $213,000 | $619,000 |
| Total Current Liabilities | $2.4M | $2.1M | $793,000 | $926,000 | $3.5M | $3.5M | $1.1M | $637,000 | $13.0M | $15.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $2.4M | $2.1M | $793,000 | $926,000 | $3.9M | $3.9M | $1.4M | $841,000 | $13.8M | $16.7M |
| Retained Earnings | -$112.5M | -$131.0M | -$138.9M | -$144.4M | -$154.2M | -$173.5M | -$183.4M | -$188.7M | -$83.7M | -$189.2M |
| Total Equity | $22.2M | $10.3M | $6.0M | $7.6M | $46.5M | $51.0M | $41.7M | $37.0M | $382.2M | $471.9M |
| Total Debt | 0 | 0 | 0 | $25,000 | $450,000 | $483,000 | $383,000 | $280,000 | $968,000 | $1.9M |
| Net Debt | -$21.2M | -$11.8M | -$6.6M | -$8.3M | -$48.6M | -$52.9M | -$42.1M | -$37.2M | -$374.7M | -$335.1M |
| Working Capital | $19.0M | $10.2M | $6.0M | $7.6M | $46.5M | $50.9M | $41.6M | $37.0M | $363.8M | $328.5M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 38.51 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 49.15 |
Profitability
| Return on Equity | -20.76% |
| Return on Invested Capital | -13.88% |
| Return on Assets | -11.66% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: DNTH · XNCR · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of ORKA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks